Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

EHA 2022 | Responses to avapritinib in patients with advanced systemic mastocytosis

Tracy George • 12 Jun 2022
EHA 2022
Myeloproliferative Neoplasms Rare Diseases Systemic Mastocytosis Avapritinib

Tracy George, MD, ARUP Laboratories, University of Utah, Salt Lake City, UT, discusses the efficacy of avapritinib in patients with advanced systemic mastocytosis. In this video, Dr George highlights the decrease in mast cell burden and hypercellularity in the bone marrow and the promise of this agent for the treatment of systemic mastocytosis. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Disclosures

Consultant, cogent blueprint

More from Tracy George

Emerging novel agents for the treatment of mastocytosis
1:44
Emerging novel agents for the treatment of mastocytosis
Tracy George • 12 Jun 2022
Unmet needs and challenges in mastocytosis
1:49
Unmet needs and challenges in mastocytosis
Tracy George • 12 Jun 2022
Emerging targeted agents in the field of mastocytosis
0:37
Emerging targeted agents in the field of mastocytosis
Tracy George • 1 Apr 2021
Changes in mast cell number & immunophenotype in patients with mastocytosis treated with avapritinib
3:37
Changes in mast cell number & immunophenotype in patients with mastocytosis treated with avapritinib
Tracy George • 1 Apr 2021

Related Videos

Federated learning to train generative AI models for diagnosis & prognosis of hematological diseases
2:08
Federated learning to train generative AI models for diagnosis & prognosis of hematological diseases
Tracy George • 7 Dec 2025
Guidance for selecting between JAK inhibitors in the frontline and second-line setting for MF
1:26
Guidance for selecting between JAK inhibitors in the frontline and second-line setting for MF
Tracy George • 6 Dec 2025
An overview of ongoing Phase III trials investigating novel treatment options for myelofibrosis
1:40
An overview of ongoing Phase III trials investigating novel treatment options for myelofibrosis
Tracy George • 6 Dec 2025
The management of patients with ET or PV during pregnancy
3:32
The management of patients with ET or PV during pregnancy
Tracy George • 7 Dec 2025
The content of VJHemOnc is intended for healthcare professionals